Verve Therapeutics CFO Disposes of 180,000 Shares Following Merger Agreement

Strategic Insights -

On July 25, 2025, Dorval Allison, Chief Financial Officer of Verve Therapeutics, Inc. [ VERV ], disposed of 180,000 shares at the rate of $13 per share. This disposal was made in accordance with the terms of the Merger Agreement, which outlines the automatic cancellation of certain stock options and the entitlement to cash payments in lieu thereof. These cash payments are calculated based on the total number of shares subject to the cancelled options and the cash payment per CVR holder.

Key Takeaways:

  • Dorval Allison, Chief Financial Officer of Verve Therapeutics, Inc. [ VERV ], disposed of 180,000 shares at a rate of $13 per share on July 25, 2025.
  • The disposal was made in accordance with the Merger Agreement, which includes provisions for the automatic cancellation of certain stock options and the entitlement to cash payments in lieu thereof.
  • The cash payments for the cancelled options are calculated based on the total number of shares subject to the options and the cash payment per CVR holder.
  • Verve Therapeutics, Inc. [ VERV ] filed a Form 4 with The Securities and Exchange Commission on July 28, 2025, disclosing the details of Dorval Allison's share disposal.
  • The Merger Agreement outlines the process for calculating and making the cash payments to holders of cancelled options.

Statistics:

  • 180,000 shares disposed of by Dorval Allison on July 25, 2025
  • $2,340 (180,000 shares x $13 per share) gross proceeds from the disposal
  • 1 Form 4 filed by Verve Therapeutics, Inc. [ VERV ] with The Securities and Exchange Commission on July 28, 2025

Sources:

  • Form 4 furnished by Verve Therapeutics, Inc. [ VERV ] to the Securities and Exchange Commission on July 28, 2025
  • The Securities and Exchange Commission's website (no specific date mentioned)